Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261786 | 0.87 | MAOB (0.65) | MAOBGRM5NR4A2PARP10MAOA | |
| SCHEMBL10727153 | 0.82 | LMNA (0.55) | MAOBNR4A2MAOA | |
| SCHEMBL22874674 | 0.82 | MAOB (0.71) | MAOBNR4A2PARP10MAOAFFAR1 | |
| SCHEMBL22967760 | 0.81 | MAOB (0.65) | MAOBGRM5NR4A2PARP10MAOA | |
| SCHEMBL8276628 | 0.80 | MAOB (0.73) | MAOBNR4A2PARP10MAOAFFAR1 | |
| SCHEMBL22874577 | 0.80 | MAOB (0.60) | MAOBGRM5NR4A2PARP10MAOA | |
| SCHEMBL27521276 | 0.80 | MAOB (0.77) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL21340832 | 0.79 | MAOB (0.79) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL10136590 | 0.79 | MAOB (0.71) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL5038027 | 0.79 | MAOB (0.71) | MAOBNR4A2PARP10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MAOB 2519/4885GRM5 2512/4885NR4A2 2105/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAOB 230/4885GRM5 2256/4885NR4A2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.